The company has received a subpoena from HHS' OIG as part of an investigation into possible improper billing of its hereditary cancer tests to Medicare and Medicaid.
FDA's blessing for 23andMe's test that gauges select BRCA1/2 variants has the cancer community worried about whether consumers will understand its limitations.
The firm reported total revenues of $194 million, compared to $196.5 million in Q2 2017, but beat the consensus Wall Street estimate of $188.8 million.
The LOHGIC algorithm is currently being used to analyze tumor sequencing assay results as part of the Rutgers Cancer Institute's precision medicine program.
At the Precision Medicine World Conference this week, researchers discussed how they plan to return genomic results to participants of research-focused sequencing studies.
The health system has changed the way it offers patients pharmacogenomics and has mandated a new assessment in annual visits intended to identify patients eligible for other genetic tests.
The investment bank said that an edit to CMS guidelines impacts payments for hereditary cancer testing, and could present Myriad with revenue and EPS headwinds.
Those involved in the project hope to demonstrate that a screening program that provides BRCA testing to women starting age 30 can be cost-effective and a public health benefit.
Geisinger is hoping to help others around the country implement precision medicine, which requires significant investment in genomics expertise, as well as infrastructural and operational changes.
For the three months ended Sept. 30, the firm reported total revenues of $190.2 million, compared to $177.5 million in Q1 2017, beating the consensus Wall Street estimate.
Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.
Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.
Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.
In Nature this week: sequenced genomes of five additional Neanderthals, and more.